State and territory governments provide access to COVID-19 treatments
The National Medical Stockpile (NMS) distributes approved COVID-19 treatments.
Your local state or territory government gives health professionals access to these treatments. Check with your local health department about their supply arrangements.
You do not need to apply to us or via a hospital.
Process for states and territories
State and territory governments access supplies by contacting the NMS. We will work through the process with them.
Clinical criteria for access
We have criteria for access to treatments.
Clinical indications for treatment
As part of the regulatory approval process, the Therapeutic Goods Administration (TGA) publishes a range of regulatory information for health professionals and consumers including a medicine’s approved indication, target population, dose, method of administration, contraindications and any special warnings and precautions for use.
This information is publicly available through the Product Information, Consumer Medicine Information and Decision Summary, among others, which can be accessed at the Australian Register of Therapeutic Goods or COVID-19 treatments.
Access to COVID-19 treatments outside of Pharmaceutical Benefits Scheme is managed by the states and territories based on health advice. Further information about public-health orders may be found on state and territory government websites.
Treatments secured for the NMS
We have secured supplies of the following COVID-19 treatments for the NMS:
- nirmatrelvir and ritonavir (Paxlovid®)
- molnupiravir (Lagevrio®)
- tixagevimab and cilgavimab (Evusheld®)
- casirivimab and imdevimab (Ronapreve®)
- sotrovimab (Xevudy®)
- remdesivir (Veklury®).
We deploy them through a consistent national model.
The COVID-19 Vaccines and Treatments for Australia - Science and Industry Technical Advisory Group (SITAG) advises the Australian Government on the purchasing and manufacturing of COVID-19 vaccines and treatments.